of the retroviral vector is described in the "Response to the 
Points to Consider." Briefly, it utilizes the MoMuLv enhancer to 
stimulate expression of the Rev M10 gene. In the control, a 
population of cells derived from the same isolation procedure 
will be transduced within a nearly identical retroviral vector 
which contains a frameshift at the initiation code of Rev M10 and 
does not produce a functional gene product. The half-life of 
cells which express Rev M10 will be compared to those which lack 
the open reading frame. These two populations will be 
distinguished using a limited dilution PCR of cells derived from 
the peripheral blood with primers specific to each vector. In 
this way, the numbers of cells which persist as a function of 
time will be determined, and the half-life of cells transduced 
with each vector will be assessed. In addition, differences in 
survival of cells stimulated by aCD3 and IL-2, vs. qCD 3 and aCD28 
will be compared. 
In a second group of patients, the Rev M10 gene will be 
introduced with a non-viral vector, using biolistic injection 
with linearized plasmids in T cells. In this case, a plasmid 
containing the Rous sarcoma virus enhancer linked to the TAR 
region of HIV driving expression of M10 will be used, since we 
have found it to show greater efficacy in electroporation 
experiments (Section 13, Preliminary Data). 
Patients will be admitted to the Clinical Research Center at 
The University of Michigan Medical Center after the relevant 
eligibility criteria have been met. The pre-treatment evaluation 
will be performed as described in Section 9. Patients undergoing 
Recombinant DNA Research, Volume 18 
[17] 
